Table 3.
Primary and Secondary Outcomes in Patients Taking DOAC Compared To Patients Taking VKA
| VKA n = 2,256 | DOAC n = 2,656 | HR (95% CI) | p | |
|---|---|---|---|---|
| Primary outcome | ||||
| Composite endpointa | 485 events/3,207 patient‐years (15.1%/y) | 272 events/2,479 patient‐years (11.0%/y) | 0.82 (0.66–1.00) | 0.05 |
| Secondary outcomes | ||||
| Recurrent AIS | 137 events/3,229 patient‐years (4.2%/y) | 110 events/2,484 patient‐years (4.4%/y) | 0.91 (0.70–1.19) | 0.5 |
| ICH | 52 events/3,302 patient‐years (1.6%/y) | 22 events/2,549 patient‐years (0.9%/y) | 0.42 (0.24–0.71) | <0.01 |
| Mortality | 358 events/3,324 patient‐years (10.8%/y) | 161 events/2,556 patient‐years (6.3%/y) | 0.83 (0.68–1.03) | 0.09 |
Given as number of events and total follow‐up time (annualized event rate).
a
Composite endpoint: acute ischemic stroke (AIS), intracranial hemorrrhage (ICH), and mortality.